Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 8/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | DRD5 | P21918 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504161 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880201 | 0.98 | CHRM2 (0.96) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881870 | 0.95 | CHRM2 (0.91) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881344 | 0.95 | CHRM2 (0.90) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881459 | 0.94 | CHRM2 (0.89) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881253 | 0.93 | CHRM2 (0.86) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880466 | 0.92 | CHRM2 (0.85) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8879988 | 0.92 | CHRM2 (0.85) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881541 | 0.91 | CHRM2 (0.83) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8878832 | 0.91 | CHRM2 (0.83) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | claimed |
| US-5641772-A | Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation | DR. KARL THOMAE GMBH (DE) | 1997-06-24 | — | — | US | claimed |
| US-5610155-A | ALZHEIMER'S | DR. KARL THOMAE GMBH (DE) | 1997-03-11 | — | — | US | claimed |
| EP-0508370-B1 | Condensed diazepinones, process for their preparation and compositions containing them for the treatment of the central nervous system and to enhance cerebral perfusion | THOMAE GMBH DR K (DE) | 1996-07-03 | — | — | EP | claimed |
| EP-0508370-A1 | Condensed diazepinones, process for their preparation and compositions containing them for the treatment of the central nervous system and to enhance cerebral perfusion | Dr. Karl Thomae GmbH (DE) | 1992-10-14 | — | — | EP | claimed |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3324966-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | Chase Pharmaceuticals Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| WO-2017015349-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-01-26 | — | — | WO | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-5641772-A | Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation | DR. KARL THOMAE GMBH (DE) | 1997-06-24 | — | — | US | disclosed |
| US-5610155-A | ALZHEIMER'S | DR. KARL THOMAE GMBH (DE) | 1997-03-11 | — | — | US | disclosed |
| EP-0508370-B1 | Condensed diazepinones, process for their preparation and compositions containing them for the treatment of the central nervous system and to enhance cerebral perfusion | THOMAE GMBH DR K (DE) | 1996-07-03 | — | — | EP | disclosed |
| EP-0508370-A1 | Condensed diazepinones, process for their preparation and compositions containing them for the treatment of the central nervous system and to enhance cerebral perfusion | Dr. Karl Thomae GmbH (DE) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | CHRM2 1575/4885CHRM1 2790/4885CHRM3 1488/4885 |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHRM2, CHRM1, CHRM4 | CHRM2 1/4885CHRM1 2/4885CHRM3 5/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | CHRM2 367/4885CHRM1 115/4885CHRM3 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.